AD-17002

AD-17002 is an investigational intranasal immunotherapy developed by Advagene Biopharma and Taipei Medical University. It consists of a genetically engineered, detoxified *Escherichia coli* heat-labile enterotoxin (LTh(αK)) adjuvant combined with house dust mite allergen. The drug is designed to modulate the immune response, primarily by enhancing the production of type I and III interferons from mucosal epithelial cells, which can help regulate allergic reactions and boost antiviral immunity. Preclinical studies have shown that it can reduce viral load and lung damage in animal models of SARS-CoV-2 infection. In clinical trials, it has been evaluated for asthma (especially eosinophilic asthma), house dust mite allergic rhinitis, and COVID-19. The therapy is administered as a nasal spray and has demonstrated safety, tolerability, immunomodulatory effects, and potential efficacy in reducing symptoms or viral load in these indications[1][2][5][6][7][8].

Brand names

LT-Allergy

Other names

Airway allergy immunotherapy - Advagene BioPharma